Replies to post #2191 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

>It seems like the story here is 100X potency => once daily dose with wiggle room to fine tune safety on the HBV. But the HBV trials are going to consume more time and money. Will and/or to what extent will NVS carry the financing of the HBV trials.<

You mean HCV, not HBV. (IDIX does not have another HBV drug in the pipeline.)

>With the 1st gen NVS was paying for the trials 100% at the end, right?<

After NVS exercised its option to license NM283 in March 2007, NVS paid 100% of the development costs (until the compound was killed).

>Will the same model hold?<

The same general structure will hold for any of IDIX’s pipeline drugs that NVS chooses to license; however, the specific terms will vary from compound to compound.